Hospitals across the UK are taking part in a national research trial to identify the safest and most effective blood-thinning treatment for mitral regurgitation.

Led by researchers at James Cook University Hospital, a total of 30 cardiac centres across the UK will take part in the pioneering AFFECT trial. It aims to identify the safest and most effective blood-thinning treatment to use after heart valve surgery for patients who also have a heart rhythm problem.

Each year, thousands of patients have surgery for mitral regurgitation, a common heart condition where the mitral valve fails to close tightly, allowing blood to leak backwards into the heart atrium instead of pumping forward to the body. This forces the heart to work harder, which can lead to fatigue, shortness of breath, and potential heart failure.

If these patients also have a heart rhythm issue, they usually need blood-thinning medication to reduce their risk of having a stroke or other complications after surgery.

Current national and international guidelines recommend using a vitamin K antagonist (VKA) such as warfarin. But there is a newer group of medicines known as direct oral anticoagulants (DOACs) which are also widely used now.

The study aims to recruit 1,282 adults who are having mitral valve repair surgery at cardiothoracic centres across the UK. Eligible patients will be invited to take part by their clinical teams. 

Study will guide national treatment decisions

Participants will be randomly allocated to receive either a DOAC or a VKA, and treatment will start before they leave hospital. They will be closely monitored for at least 12 months, with further annual check-ups for up to four years. Researchers will assess a range of outcomes, including stroke prevention, quality of life and cost-effectiveness. 

The AFFECT trial aims to identify which treatment option offers the best long-term outcomes for patients.

“This is an important question for both patients and clinicians,” said Enoch Akowuah, consultant cardiac surgeon and chief investigator for the AFFECT trial at South Tees Hospitals NHS Trust, part of the hospital group, University Hospitals Tees. “We know anticoagulation is essential for patients with atrial fibrillation after mitral valve repair, but we do not yet know which treatment offers the best balance of safety and protection. The AFFECT Trial will provide high-quality evidence to guide national treatment decisions and improve long-term outcomes for patients across the UK and internationally.”